A stem cell-based therapy with the potential to treat multiple sclerosis


  • In people with multiple sclerosis (MS), repeated intrathecal (IT) injections of autologous mesenchymal stem cell-derived neural progenitors (MSC-NPs) are safe for long-term use, and can lead to a 2-year post-treatment sustained reversal in disability or lack of disease progression.

Why this matters ?

    This study adds to the limited data on the long-term safety and efficacy of IT-MSC-NP injections in people with MS.

International Medical Press is a global provider of independent medical education. Its mission is to provide healthcare professionals with high-quality, trusted medical information with the aim of helping optimize patient care.

No responsibility is assumed by International Medical Press for any injury and/or damage to persons or property through negligence or otherwise, or from any use or operation of any methods, products, instructions, or ideas contained in the material herein. Because of rapid advances in the medical sciences, International Medical Press recommends that independent verification of diagnoses and drug dosages should be made. The opinions expressed do not reflect those of International Medical Press or the sponsor. International Medical Press assumes no liability for any material contained herein.